Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma

被引:4
|
作者
Gupta, Vikas A. [1 ]
Nooka, Ajay K. [1 ]
Lonial, Sagar [1 ]
Boise, Lawrence H. [1 ]
机构
[1] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA
来源
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY | 2013年 / 3卷
关键词
proteasome inhibitor; bortezomib; pharmacology; safety; efficacy;
D O I
10.2147/BLCTT.S31867
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Treatment of refractory and/or relapsed multiple myeloma has been a challenging problem for over 20 years. However, we have made significant progress addressing this disease with the use of bortezomib, the first in class proteasome inhibitor, and the immunomodulatory agents, thalidomide and lenalidomide. Carfilzomib, the second-generation proteasome inhibitor, has also been approved for treatment of relapsed/refractory multiple myeloma. Carfilzomib is a highly selective and potent inhibitor of proteasome chymotrypsin-like activity. Phase I and II clinical trials have reported an acceptable toxicity profile, with manageable thrombocytopenia and anemia being the most common side effects. Peripheral neuropathy, a frequent dose-limiting side effect of bortezomib, was rare. Further, carfilzomib demonstrated encouraging single-agent activity and appeared to be effective even in patients refractory to bortezomib. Based on these promising data, carfilzomib is moving forward into Phase III trials for relapsed multiple myeloma and is also being investigated as front-line combination therapy for patients with newly diagnosed myeloma.
引用
收藏
页码:41 / 51
页数:11
相关论文
共 50 条
  • [31] Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
    Dubey, A. P.
    Khatri, Sameer
    Maggo, Sachin
    Singh, Nilabh K.
    Sharma, Durgesh
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (06) : 846 - 849
  • [32] Treatment of relapsed or refractory multiple myeloma
    Maiolino, Angelo
    Garnica, Marcia
    LEUKEMIA RESEARCH, 2018, 73 : S3 - S3
  • [33] Treatment of Relapsed/Refractory Multiple Myeloma
    Kastritis, Efstathios
    Palumbo, Antonio
    Dimopoulos, Meletios A.
    SEMINARS IN HEMATOLOGY, 2009, 46 (02) : 143 - 157
  • [34] Treatment of relapsed and refractory multiple myeloma
    Engelhardt, M.
    Graziani, G.
    Javorniczky, R.
    Neubauer, J.
    Koehler, M.
    Herget, G. W.
    Waesch, R.
    ONKOLOGE, 2018, 24 (08): : 613 - 624
  • [35] Treatment of relapsed and refractory multiple myeloma
    Seema Singhal
    Jayesh Mehta
    Current Treatment Options in Oncology, 2003, 4 (3) : 229 - 237
  • [36] Treatment of relapsed and refractory multiple myeloma
    Sonneveld, Pieter
    Broijl, Annemiek
    HAEMATOLOGICA, 2016, 101 (04) : 396 - 406
  • [37] TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Zamagni, E.
    Tacchetti, P.
    Barbato, S.
    Cavo, M.
    HAEMATOLOGICA, 2021, 106 (10) : 215 - 218
  • [38] Treatment of relapsed and refractory multiple myeloma
    Lee, Ji Hyun
    Kim, Sung-Hyun
    BLOOD RESEARCH, 2020, 55 : 43 - 53
  • [39] Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
    Jakubowiak, Andrzej J.
    Jasielec, Jagoda K.
    Rosenbaum, Cara A.
    Cole, Craig E.
    Chari, Ajai
    Mikhael, Joseph
    Nam, Jennifer
    McIver, Amanda
    Severson, Erica
    Stephens, Leonor A.
    Tinari, Kathryn
    Rosebeck, Shaun
    Zimmerman, Todd M.
    Hycner, Tyler
    Turowski, Agata
    Karrison, Theodore
    Zonder, Jeffrey A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (04) : 549 - 560
  • [40] Efficacy of Carfilzomib in the Treatment of Relapsed and (or) Refractory Multiple myeloma: a Meta Analysis of Individual Patient Data from Clinical Trials
    Chen, Runzhe
    Chen, Baoan
    Ge, Zheng
    BLOOD, 2016, 128 (22)